Neurophysiology

WIMI Hologram Academy: The application of virtual reality technology in balance function disorder after cerebral apoplexy

Retrieved on: 
Wednesday, April 27, 2022
Cloud, Statistics, Computer, Injury, Feedback, Disability, CVA, Stroke, NASDAQ, Research, Work, Rehabilitation, Science, Posture, GLOBE, Subarachnoid hemorrhage, Patient, Berg Balance Scale, Muscle, VR, WIMI, Walking, Cerebral infarction, Technology, Movement, Proprioception, Ischemia, Method, Maintenance, Falls, AI, Intracranial hemorrhage, Apoplexy, Hemiparesis, Partnership, Risk, Neurophysiology, Nature, Pharmaceutical industry, Medical imaging

Typically it includes cerebral hemorrhage, cerebral infarction, subarachnoid hemorrhage and other diseases.Scientists from WIMI Hologram Academy of WIMI Hologram Cloud Inc. (NASDAQ: WIMI) have studied the application of virtual reality technology in balance function disorder after cerebral apoplexy.

Key Points: 
  • Typically it includes cerebral hemorrhage, cerebral infarction, subarachnoid hemorrhage and other diseases.Scientists from WIMI Hologram Academy of WIMI Hologram Cloud Inc. (NASDAQ: WIMI) have studied the application of virtual reality technology in balance function disorder after cerebral apoplexy.
  • Virtual reality technology uses a computer to simulate the real world and allows the user to experience the virtual world.
  • Virtual reality technology uses computers to synthesize 3D environment models and apply these models to create and experience virtual worlds.
  • The study indicated that by combining virtual reality rehabilitation exercises with conventional rehabilitation training, patientslimb function, neurological function, balance function, as well as their life quality can be effectively improved.

Anna Shor, MD, is recognized by Continental Who's Who

Retrieved on: 
Monday, April 11, 2022
Spinal cord, Ministry of Health (New South Wales), U.S. News & World Report, University, NYU, NYU Langone Health, Family, Clinical, Multimedia, U.S. News & World Report Best Hospitals Rankings, Education, News, American Board of Commissioners for Foreign Missions, Certification, Research, Associate, American Board of Psychiatry and Neurology, Hospital, Neuropsychiatry, Medical degree, Continental, MD, Nervous system, Health, United State, Surgeon, ABPN, Muscle, Brain, Physician, Department of Neurology, Xuanwu hospital, Department, Neuromuscular Disorders, Disability, Committee on Medical Aspects of Radiation in the Environment, Arthropathy, Patient, NYU Langone Hospital – Brooklyn, Pharmaceutical industry, Medical device, Medicine, Medicine, Epilepsy, Pharmacy, Psychiatry, Electromyography, Neurophysiology, Neurology

BROOKLYN, N.Y., April 11, 2022 /PRNewswire/ -- Anna Shor, MD, is being recognized by Continental Who's Who as a Distinguished Physician in Neurology and in acknowledgment of her work at NYU Langone: Clinical Neurophysiology Associates.

Key Points: 
  • BROOKLYN, N.Y., April 11, 2022 /PRNewswire/ -- Anna Shor, MD, is being recognized by Continental Who's Who as a Distinguished Physician in Neurology and in acknowledgment of her work at NYU Langone: Clinical Neurophysiology Associates.
  • Dr. Shor attended Nicolae Testemianu State University of Medicine and Pharmacy in Moldova, graduating with her Medical Degree.
  • She then attended North Shore LIJ, where she gained experience in a Neurology residency (2010) and an Epilepsy Fellowship (2011).
  • The doctor has recently been recognized with a profile feature in Health News today and US News & World Report.

BioMech Golf Releases BioMech PUTT for Android, Expands Putter Line with BioMech MAX

Retrieved on: 
Monday, March 21, 2022
Company, Biomech, Golf, Genetics, PGA Tour, App store, Physiology, IOS, Health, Mathematics, Quality of life, LLC, Review, Stroke, Anatomy, Neurophysiology, Physics, Acceleration, Feedback, Biophysics, Medical device, Android

"BioMech PUTT helps golfers of all levels improve their skills by providing consistent and immediate performance feedback.

Key Points: 
  • "BioMech PUTT helps golfers of all levels improve their skills by providing consistent and immediate performance feedback.
  • Fun and easy to use, the BioMech PUTT app measures and displays face and loft angles, timing, and acceleration changes throughout the stroke.
  • With BioMech PUTT, golfers can set thresholds and alerts and review metrics for individual putts or session averages.
  • Pivoting to the Company's other major advancement in golf, the BioMech MAX putter is built heavier than earlier versions to deliver a better feel and improved performance.

Athira Pharma Announces Publication of Phase 1 Results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease

Retrieved on: 
Tuesday, February 22, 2022
ACT, Alzheimer's disease, ERP, Securities Exchange Act of 1934, Security (finance), Neurodegeneration, Neurophysiology, COVID-19, National, Athira Pharma, Hepatocyte growth factor, Private Securities Litigation Reform Act, Research, National Institute, Pharmacokinetics, WHO, Investment, American Journal of Alzheimer's Disease & Other Dementias, Safety, U.S. Securities and Exchange Commission, INN, Securities Act of 1933, HGF, Journal, Male, Dementia, Lists of diseases, Doctor of Philosophy, Population, Twitter, International, NASDAQ, Volunteering, LinkedIn, Brain, Cognition, Instagram, Forward-looking statement, Patient, GLOBE, Quantitative electroencephalography, SHAPE, World, Nature, Lewy body, MD, MET, WHO Expert Committee on Leprosy, Pharmaceutical industry, Fine chemical, Dietary supplement, Facebook, L. Athira Krishna

BOTHELL, Wash., Feb. 22, 2022 (GLOBE NEWSWIRE) --  Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the peer-reviewed publication of data from a Phase 1 clinical trial of fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease.

Key Points: 
  • These data support our ongoing Phase 2 ACT-AD and Phase 3 LIFT-AD trials evaluating fosgonimeton's potential as a treatment for Alzheimers disease.
  • We look forward to sharing the Phase 2 ACT-AD top-line data in the second quarter of 2022.
  • The randomized, placebo-controlled, double-blind Phase 1 clinical trial of fosgonimeton enrolled a total of 88 subjects.
  • These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements.

BioMech Sets New Standard of Care with AI-enabled, Clinically Actionable Real-time Motion Analytics for Improved Healthcare Outcomes

Retrieved on: 
Tuesday, February 8, 2022
Max-min fairness, Artificial intelligence, Algorithm, Mathematics, Gait, Biomech, Quality of life, Risk, Technology, Patient, Anatomy, Biophysics, Health, Genetics, Therapy, Power, Motion, Insurance, Feedback, Machine learning, Neurophysiology, LLC, Medical device

"Functional motion is a powerful measure of health and includes such fundamental aspects as balance, symmetry, range of motion, voluntary motor responses to stimuli and complex movements like gait," said BioMech Co-Founder Frank Fornari, Ph.D .

Key Points: 
  • "Functional motion is a powerful measure of health and includes such fundamental aspects as balance, symmetry, range of motion, voluntary motor responses to stimuli and complex movements like gait," said BioMech Co-Founder Frank Fornari, Ph.D .
  • Empting, M.D., Director, Independent Neurodiagnostic Clinic, noting that BioMech Lab lets them objectively assess and mitigate fall risk and quantitatively monitor for medication effects and side effects.
  • We are improving patient outcomes and doing so in a fashion that allows clinicians and insurance carriers alike to monitor rates of improvement and functionality."
  • Headquartered in Richmond, Va., BioMech develops and distributes state of the art, real-time motion analytics that quantify and improve patient/user outcomes in healthcare, sports/wellness, and industrial sectors.

The Worldwide Medical Electrodes Industry is Expected to Reach $2.1 Billion by 2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 22, 2021
Biotechnology, Surgery, Medical Devices, Hospitals, Health, Research, USD, Growth, Hospital, IOM, Patient, Adoption, ECG, Medicine, Fortis Healthcare, Risk, Disposable product, Neurophysiology, EMG, Investment, Electrode, Ageing, CAGR, Awareness, Conditional sentence, EEG, Population, Wet, Prevalence, Incidence, Medical device

Diagnostic medical electrodes segment is expected to dominate the market during the forecast period and is also expected to grow at the highest CAGR during the forecast period.

Key Points: 
  • Diagnostic medical electrodes segment is expected to dominate the market during the forecast period and is also expected to grow at the highest CAGR during the forecast period.
  • Based on products, the medical electrodes market is segmented into diagnostic medical electrodes and therapeutic medical electrodes.
  • In 2020, the diagnostic medical electrodes segment accounted for the largest share of the medical electrodes market.
  • Based on usability, medical electrodes are categorized into disposable electrodes and reusable electrodes.

MX Names Shawn Lindquist Chief Legal Officer

Retrieved on: 
Wednesday, October 13, 2021
Organization, Novell, Data science, Acceleration, SAP, Technology, Encore Capital Group, Financial technology, LinkedIn, McKinsey & Company, Wells Fargo, Growth, Initial public offering, Marketing, Neurophysiology, Economics, SanDisk, Open banking, Fis, IPO, H&R Block, Open, Science and technology in Asia, MX, Development of non-profit housing in the United States, Final good, Company, Sunrun, Commerce, CEO, Wilson Sonsini Goodrich & Rosati, Crystal, Brigham Young University, Bose, BTS, Twitter, Education, Adobe Inc., Public sector, Acquisition, Shawn, Management

Shawn Lindquist joins MX as the company's first chief legal officer.

Key Points: 
  • Shawn Lindquist joins MX as the company's first chief legal officer.
  • "We are excited to welcome Shawn Lindquist as our Chief Legal Officer as we continue our growth trajectory and market leadership through best-in-class product innovation, strategic partnerships, and operational excellence."
  • Prior to joining MX, Shawn served as the chief legal officer of Vivint Smart Home, Inc., a leading smart home company from May 2016 through August 2021.From February 2014 to May 2016, he served as the chief legal officer of Vivint Solar, Inc., a leading distributed solar energy company acquired by Sunrun Inc. in 2020.From 2010 to 2014, he served as the chief legal officer of Fusion-io, Inc., a leading provider of flash memory solutions for application acceleration acquired by Sandisk Corporation in 2014.
  • "MX has positioned itself at the center of a transformation happening within the financial industry as organizations everywhere look to connect to the world's financial data to power new, intelligent money experiences for their customers," said Shawn Lindquist, chief legal officer of MX.

BrainsWay Announces Prominent Addition to Scientific Advisory Board

Retrieved on: 
Tuesday, October 12, 2021
Private Securities Litigation Reform Act, Company, NASDAQ, Deep, Insurance, Genta (company), Doctor of Philosophy, SAB, Department, Addiction, UCSD, COVID-19, Mental health, Tic disorder, GLOBE, Failure, Uncertainty, Transcranial magnetic stimulation, Psychiatry, CAMH, Brainsway, Legislation, Annual report, FDA, MD, Lists of diseases, Health, News, University, Review, School, U.S. Securities and Exchange Commission, Knowledge, CEO, Awareness, TASE, Patient, Neurophysiology, Research, Technology, TMS, University of California, San Diego, Center, Pharmaceutical industry

and JERUSALEM, Oct. 12, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay" or the Company), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the addition of Dr. Zafiris Jeff Daskalakis to BrainsWays scientific advisory board (SAB).

Key Points: 
  • and JERUSALEM, Oct. 12, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay" or the Company), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the addition of Dr. Zafiris Jeff Daskalakis to BrainsWays scientific advisory board (SAB).
  • We are extremely honored that Dr. Daskalakis has agreed to join our world-class scientific advisory board, said Christopher von Jako, PhD, President and CEO of BrainsWay.
  • Dr. Daskalakis has authored more than 450 peer-reviewed publications and serves on the editorial board of multiple journals.
  • BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy.

Nature and Science of Sleep Journal Publishes a New Study Examining the Effect of the COVID-19 Pandemic on Dreams

Retrieved on: 
Friday, October 8, 2021
List of Dove Medical Press academic journals, Mental health, Dove Medical Press, Nature, COVID-19, DRF, Genetics, Female, Taylor & Francis, Nightmare, United Kingdom, Access, Pandemic, Dream, Medicine, Science, Neurophysiology, Technology, Open access, Pharmaceutical industry, Publishing

NEW YORK, Oct. 8, 2021 /PRNewswire-PRWeb/ --The Dove Medical Press journal, Nature and Science of Sleep, has published a new study examining the effect of the COVID-19 Pandemic on dreams.

Key Points: 
  • NEW YORK, Oct. 8, 2021 /PRNewswire-PRWeb/ --The Dove Medical Press journal, Nature and Science of Sleep, has published a new study examining the effect of the COVID-19 Pandemic on dreams.
  • The authors conducted a cross-sectional web survey of 19,355 participants in 14 countries from May to July 2020.
  • They also found that female gender, nightmares, sleep talking, sleep maintenance problems and repeated disturbing thoughts were associated with high DRF.
  • The full article can be accessed here: https://www.dovepress.com/how-our-dreams-changed-during-the-covid-19-pan...
    Nature and Science of Sleep (5.346 IF) is an international, peer-reviewed, open access journal covering all aspects of sleep science and sleep medicine, including the neurophysiology and functions of sleep, the genetics of sleep, sleep and society, biological rhythms, dreaming, sleep disorders and therapy, and strategies to optimize healthy sleep.

PhotoPharmics Brings Renowned Experts in Parkinson’s Disease and Other Neurodegenerative Diseases to Advisory Board

Retrieved on: 
Thursday, September 16, 2021
Research, Medical Devices, Clinical Trials, Biotechnology, Other Health, Health, General Health, Other Science, Science, Neurology, Birmingham, Biomarker, Behavior, University, Neurophysiology, Technology, A Call for Unity, Movement disorders, Depression, Seasonal affective disorder, Doctor of Philosophy, Patient, CSAB, Anxiety, Neurodegeneration, MS, Michael, Parkinson's disease, Safety, Children's Mercy Hospital, Coronavirus Scientific Advisory Board (Turkey), Solution, Book, Mount Sinai Hospital, Vanderbilt University, Multimedia, Review, Clinical, The Michael J. Fox Foundation, Sleep, DBS, Organization, Diagnosis, Cognition, Internet, Research, Parkinson, University of Kansas Medical Center, Exercise, Deep brain stimulation, Pharmaceutical industry, Management

Clinical-stage medical device maker PhotoPharmics today announced a Clinical & Scientific Advisory board (CSAB) comprised of six leading experts in Parkinsons disease (PD) and other neurodegenerative diseases.

Key Points: 
  • Clinical-stage medical device maker PhotoPharmics today announced a Clinical & Scientific Advisory board (CSAB) comprised of six leading experts in Parkinsons disease (PD) and other neurodegenerative diseases.
  • The boards aim is to provide clinical and scientific advice and direction to support the PhotoPharmics mission to "Improve the lives of people who suffer from neurodegenerative diseases.
  • We are extremely pleased that Dr. Olanow has agreed to chair our Advisory Board, said Kent Savage, CEO of PhotoPharmics.
  • As an emerging leader in non-invasive specialized light therapy for neurodegenerative diseases, PhotoPharmics will benefit from the advice and insight of this world-class advisory board, said Karl Kieburtz, MD, Chief Medical Officer of PhotoPharmics.